De novo lipogenesis in health and disease

Fatima Ameer, Lisa Scandiuzzi, Shahida Hasnain, Hubert Kalbacher, Nousheen Zaidi

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background De novo lipogenesis (DNL) is a complex and highly regulated metabolic pathway. In normal conditions DNL converts excess carbohydrate into fatty acids that are then esterified to storage triacylglycerols (TGs). These TGs could later provide energy via β-oxidation. In human body this pathway is primarily active in liver and adipose tissue. However, it is considered to be a minor contributor to the serum lipid homeostasis. Deregulations in the lipogenic pathway are associated with diverse pathological conditions. Scope of review The present review focuses on our current understanding of the lipogenic pathway with special reference to the causes and consequences of aberrant DNL. Major conclusions The deregulation of DNL in the major lipogenic tissues of the human body is often observed in various metabolic anomalies - including obesity, non-alcoholic fatty liver disease and metabolic syndrome. In addition to that de novo lipogenesis is reported to be exacerbated in cancer tissues, virus infected cells etc. These observations suggest that inhibitors of the DNL pathway might serve as therapeutically significant compounds. The effectiveness of these inhibitors in treatment of cancer and obesity has been suggested by previous works. General significance De novo lipogenesis - which is an intricate and highly regulated pathway - can lead to adverse metabolic consequences when deregulated. Therapeutic targeting of this pathway may open a new window of opportunity for combating various lipogenesis-driven pathological conditions - including obesity, cancer and certain viral infections.

Original languageEnglish (US)
Pages (from-to)895-902
Number of pages8
JournalMetabolism: Clinical and Experimental
Volume63
Issue number7
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Lipogenesis
Health
Obesity
Human Body
Triglycerides
Neoplasms
Virus Diseases
Metabolic Networks and Pathways
Adipose Tissue
Homeostasis
Fatty Acids
Carbohydrates
Viruses
Lipids
Liver
Therapeutics
Serum

Keywords

  • Cancer
  • De novo lipogenesis
  • Fatty Acid Synthase
  • Non-alcoholic fatty liver disease
  • Obesity

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., & Zaidi, N. (2014). De novo lipogenesis in health and disease. Metabolism: Clinical and Experimental, 63(7), 895-902. https://doi.org/10.1016/j.metabol.2014.04.003

De novo lipogenesis in health and disease. / Ameer, Fatima; Scandiuzzi, Lisa; Hasnain, Shahida; Kalbacher, Hubert; Zaidi, Nousheen.

In: Metabolism: Clinical and Experimental, Vol. 63, No. 7, 2014, p. 895-902.

Research output: Contribution to journalArticle

Ameer, F, Scandiuzzi, L, Hasnain, S, Kalbacher, H & Zaidi, N 2014, 'De novo lipogenesis in health and disease', Metabolism: Clinical and Experimental, vol. 63, no. 7, pp. 895-902. https://doi.org/10.1016/j.metabol.2014.04.003
Ameer, Fatima ; Scandiuzzi, Lisa ; Hasnain, Shahida ; Kalbacher, Hubert ; Zaidi, Nousheen. / De novo lipogenesis in health and disease. In: Metabolism: Clinical and Experimental. 2014 ; Vol. 63, No. 7. pp. 895-902.
@article{de698779f8f649fabf4e37af67bb1f55,
title = "De novo lipogenesis in health and disease",
abstract = "Background De novo lipogenesis (DNL) is a complex and highly regulated metabolic pathway. In normal conditions DNL converts excess carbohydrate into fatty acids that are then esterified to storage triacylglycerols (TGs). These TGs could later provide energy via β-oxidation. In human body this pathway is primarily active in liver and adipose tissue. However, it is considered to be a minor contributor to the serum lipid homeostasis. Deregulations in the lipogenic pathway are associated with diverse pathological conditions. Scope of review The present review focuses on our current understanding of the lipogenic pathway with special reference to the causes and consequences of aberrant DNL. Major conclusions The deregulation of DNL in the major lipogenic tissues of the human body is often observed in various metabolic anomalies - including obesity, non-alcoholic fatty liver disease and metabolic syndrome. In addition to that de novo lipogenesis is reported to be exacerbated in cancer tissues, virus infected cells etc. These observations suggest that inhibitors of the DNL pathway might serve as therapeutically significant compounds. The effectiveness of these inhibitors in treatment of cancer and obesity has been suggested by previous works. General significance De novo lipogenesis - which is an intricate and highly regulated pathway - can lead to adverse metabolic consequences when deregulated. Therapeutic targeting of this pathway may open a new window of opportunity for combating various lipogenesis-driven pathological conditions - including obesity, cancer and certain viral infections.",
keywords = "Cancer, De novo lipogenesis, Fatty Acid Synthase, Non-alcoholic fatty liver disease, Obesity",
author = "Fatima Ameer and Lisa Scandiuzzi and Shahida Hasnain and Hubert Kalbacher and Nousheen Zaidi",
year = "2014",
doi = "10.1016/j.metabol.2014.04.003",
language = "English (US)",
volume = "63",
pages = "895--902",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - De novo lipogenesis in health and disease

AU - Ameer, Fatima

AU - Scandiuzzi, Lisa

AU - Hasnain, Shahida

AU - Kalbacher, Hubert

AU - Zaidi, Nousheen

PY - 2014

Y1 - 2014

N2 - Background De novo lipogenesis (DNL) is a complex and highly regulated metabolic pathway. In normal conditions DNL converts excess carbohydrate into fatty acids that are then esterified to storage triacylglycerols (TGs). These TGs could later provide energy via β-oxidation. In human body this pathway is primarily active in liver and adipose tissue. However, it is considered to be a minor contributor to the serum lipid homeostasis. Deregulations in the lipogenic pathway are associated with diverse pathological conditions. Scope of review The present review focuses on our current understanding of the lipogenic pathway with special reference to the causes and consequences of aberrant DNL. Major conclusions The deregulation of DNL in the major lipogenic tissues of the human body is often observed in various metabolic anomalies - including obesity, non-alcoholic fatty liver disease and metabolic syndrome. In addition to that de novo lipogenesis is reported to be exacerbated in cancer tissues, virus infected cells etc. These observations suggest that inhibitors of the DNL pathway might serve as therapeutically significant compounds. The effectiveness of these inhibitors in treatment of cancer and obesity has been suggested by previous works. General significance De novo lipogenesis - which is an intricate and highly regulated pathway - can lead to adverse metabolic consequences when deregulated. Therapeutic targeting of this pathway may open a new window of opportunity for combating various lipogenesis-driven pathological conditions - including obesity, cancer and certain viral infections.

AB - Background De novo lipogenesis (DNL) is a complex and highly regulated metabolic pathway. In normal conditions DNL converts excess carbohydrate into fatty acids that are then esterified to storage triacylglycerols (TGs). These TGs could later provide energy via β-oxidation. In human body this pathway is primarily active in liver and adipose tissue. However, it is considered to be a minor contributor to the serum lipid homeostasis. Deregulations in the lipogenic pathway are associated with diverse pathological conditions. Scope of review The present review focuses on our current understanding of the lipogenic pathway with special reference to the causes and consequences of aberrant DNL. Major conclusions The deregulation of DNL in the major lipogenic tissues of the human body is often observed in various metabolic anomalies - including obesity, non-alcoholic fatty liver disease and metabolic syndrome. In addition to that de novo lipogenesis is reported to be exacerbated in cancer tissues, virus infected cells etc. These observations suggest that inhibitors of the DNL pathway might serve as therapeutically significant compounds. The effectiveness of these inhibitors in treatment of cancer and obesity has been suggested by previous works. General significance De novo lipogenesis - which is an intricate and highly regulated pathway - can lead to adverse metabolic consequences when deregulated. Therapeutic targeting of this pathway may open a new window of opportunity for combating various lipogenesis-driven pathological conditions - including obesity, cancer and certain viral infections.

KW - Cancer

KW - De novo lipogenesis

KW - Fatty Acid Synthase

KW - Non-alcoholic fatty liver disease

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=84902551389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902551389&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2014.04.003

DO - 10.1016/j.metabol.2014.04.003

M3 - Article

C2 - 24814684

AN - SCOPUS:84902551389

VL - 63

SP - 895

EP - 902

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 7

ER -